|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"furuse j"
Showing items 1-25 of 25 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2024-06-17 |
Plain language summary of the FOENIX-CCA2 study: Futibatinib for people with advanced bile duct cancer
|
Goyal, L; Meric-Bernstam, F; Hollebecque, A; Valle, JW; Morizane, C; Karasic, TB; Abrams, TA; Furuse, J; Kelley, RK; Cassier, PA; Klümpen, HJ; Chang, HM; Chen, LT; Tabernero, J; Oh, D; Mahipal, A; Moehler, M; Komatsu, Y; Ahn, DH; Epstein, RS; Halim, AB; Wacheck, V; He, YH; Liu, M; Benhadji, KA; Bridgewater, JA |
| 國家衛生研究院 |
2023-01-19 |
Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma
|
Goyal, L; Meric-Bernstam, F; Hollebecque, A; Valle, JW; Morizane, C; Karasic, TB; Abrams, TA; Furuse, J; Kelley, RK; Cassier, PA; Klümpen, HJ; Chang, HM; Chen, LT; Tabernero, J; Oh, DY; Mahipal, A; Moehler, M; Mitchell, EP; Komatsu, Y; Masuda, K; Ahn, D; Epstein, RS; Halim, AB; Fu, Y; Salimi, T; Wacheck, V; He, Y; Liu, M; Benhadji, KA; Bridgewater, JA |
| 國立成功大學 |
2023 |
Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology (IAP) & the Japan Pa
|
Hashimoto, D.;Satoi, Satoi S.;Fujii, T.;Sho, M.;He, J.;Hackert, T.;Del, Chiaro M.;Jang, Jang J.-Y.;Gulla, A.;Yoon, Yoon Y.-S.;Shan, Y.-S.;Lou, W.;Valente, R.;Furuse, J.;Oba, A.;Nagai, M.;Terai, Terai T.;Tanaka, H.;Sakai, A.;Yamamoto, T.;Yamaki, S.;Matsumoto, I.;Murakami, Y.;Takaori, K.;Takeyama, Y. |
| 臺大學術典藏 |
2022-09-15T01:08:58Z |
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies
|
Yamamoto N.; Ryoo B.-Y.; Keam B.; Kudo M.; Chia-Chi Lin; Kunieda F.; Ball H.A.; Moran D.; Komatsu K.; Takeda K.; Fukuda M.; Furuse J.; Morita S.; Doi T. |
| 臺大學術典藏 |
2022-08-19T00:21:03Z |
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion
|
Chen P.-J.; Furuse J.; Han K.-H.; CHIUN HSU; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Yeoh E.-M.; Yeo W. |
| 國家衛生研究院 |
2022-06 |
Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements
|
Goyal, L;Meric-Bernstam, F;Hollebecque, A;Morizane, C;Valle, JW;Karasic, TB;Abrams, TA;Kelley, RK;Cassier, PA;Furuse, J;Klumpen, HJ;Chang, HM;Chen, LT;Komatsu, Y;Masuda, K;Ahn, DH;Li, K;Benhadji, KA;Wacheck, V;Bridgewater, JA |
| 臺大學術典藏 |
2021-09-01T01:54:13Z |
Liver cancer working group report
|
Kudo M.; Han K.H.; Kokudo N.; ANN-LII CHENG; Choi B.I.; Furuse J.; Izumi N.; Park J.-W.; Poon R.T.; Sakamoto M. |
| 臺大學術典藏 |
2021-09-01T01:53:48Z |
Randomized phase iii study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: Gest study
|
Ueno H.; Ioka T.; Ikeda M.; Ohkawa S.; Yanagimoto H.; Boku N.; Fukutomi A.; Sugimori K.; Baba H.; Yamao K.; Shimamura T.; Sho M.; Kitano M.; ANN-LII CHENG; Mizumoto K.; Chen J.-S.; Furuse J.; Funakoshi A.; Hatori T.; Yamaguchi T.; Egawa S.; Sato A.; Ohashi Y.; Okusaka T.; Tanaka M. |
| 國家衛生研究院 |
2021-09 |
Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
|
Mohler, M;Goyal, L;Meric-Bernstam, F;Hollebecque, A;Morizane, C;Valle, JW;Karasic, TB;Abrams, TA;Kelley, RK;Cassier, P;Furuse, J;Klumpen, HJ;Chang, HM;Chen, LT;Komatsu, Y;Masuda, K;Ahn, D;He, Y;Soni, N;Benhadji, KA;Bridgewater, JA |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
|
Hagiwara Y.; Ohashi Y.; Okusaka T.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; ANN-LII CHENG; Kihara K.; Sato A.; Tanaka M. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer
|
Okusaka T.; Miyakawa H.; Fujii H.; Nakamori S.; Satoh T.; Hamamoto Y.; Ito T.; Maguchi H.; Matsumoto S.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; Chen J.S.; ANN-LII CHENG; Sato A.; Ohashi Y.; Tanaka M.; on behalf of the GEST group |
| 臺大學術典藏 |
2021-08-31T06:29:14Z |
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
|
Sangro B.; Melero I.; Wadhawan S.; Finn R.S.; Abou-Alfa G.K.; ANN-LII CHENG; Yau T.; Furuse J.; Park J.-W.; Boyd Z.; Tang H.T.; Shen Y.; Tschaika M.; Neely J.; El-Khoueiry A. |
| 臺大學術典藏 |
2021-07-03T03:34:45Z |
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion
|
PEI-JER CHEN; Furuse J.; Han K.-H.; Hsu C.; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Yeoh E.-M.; Yeo W. |
| 臺大學術典藏 |
2021-07-03T03:34:40Z |
Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
|
Yeo W.; PEI-JER CHEN; Furuse J.; Han K.-H.; Hsu C.; Lim H.-Y.; Moon H.; Qin S.; Yeoh E.-M.; Ye S.-L. |
| 國家衛生研究院 |
2021-07 |
Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
|
Goyal, L;Meric-Bernstam, F;Hollebecque, A;Morizane, C;Valle, JW;Karasic, TB;Abrams, TA;Kelley, RK;Cassier, P;Furuse, J;Klumpen, HJ;Chang, HM;Chen, LT;Komatsu, Y;Masuda, K;Ahn, D;He, YH;Soni, N;Benhadji, KA;Bridgewater, JA |
| 臺大學術典藏 |
2021-01-28T01:06:20Z |
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYnote-061): a randomised, open-label, controlled, phase 3 trial
|
Shitara K.;?Zg?Ro?Lu M.;Bang Y.-J.;Di Bartolomeo M.;Mandal? M.;Ryu M.-H.;Fornaro L.;Olesi?Ski T.;Caglevic C.;Chung H.C.;Muro K.;Goekkurt E.;Mansoor W.;Mcdermott R.S.;Shacham-Shmueli E.;Chen X.;Mayo C.;Kang S.P.;Ohtsu A.;Fuchs C.S.;Lerzo G.;O'Connor J.M.;Mendez G.A.;Lynam J.;Tebbutt N.;Wong M.;Strickland A.;Karapetis C.;Goldstein D.;Vasey P.;Van Laethem J.-L.;Van Cutsem E.;Berry S.;Vincent M.;Muller B.;Rey F.;Zambrano A.;Guerra J.;Krogh M.;Baeksgaard L.;Yilmaz M.;Elme A.;Magi A.;Auvinen P.;Alanko T.;Moehler M.;Kunzmann V.;Seufferlein T.;Thuss-Patience P.;Goekkurt E.;Hoehler T.;Haag G.;Al-Batran S.-E.;Castro H.;Lopez K.;Aguilar Vasquez M.;Sandoval M.;Lam K.O.;Cuffe S.;Kelly C.;Geva R.;Shacham-Shmueli E.;Hubert A.;Beny A.;Brenner B.;Giuseppe A.;Falcone A.;Maiello E.;Passalacqua R.;Montesarchio V.;Hara H.;Chin K.;Nishina T.;Komatsu Y.;Machida N.;Hironaka S.;Satoh T.;Tamura T.;Sugimoto N.;Cho H.;Omuro Y.;Kato K.;Goto M.;Hyodo I.;Yoshida K.;Baba H.;Esaki T.;Furuse J.;Wan Mohammed W.Z.;Hernandez Hernandez C.;Casas Garcia J.;Dominguez Andrade A.;Clarke K.;Hjortland G.;Glenjen N.;Kubiatowski T.;Jacek J.;Wojtukiewicz M.;Lazarev S.;Lancukhay Y.;Afanasayev S.;Moiseyenko V.;Kostorov V.;Protsenko S.;Shirinkin V.;Sakaeva D.;Fadeeva N.;Yong W.P.;Ng C.H.M.;Robertson B.;Rapaport B.;Cohen G.;Dreosti L.;Ruff P.;Jacobs C.;Landers G.;Szpak W.;Roh S.-Y.;Lee J.;Kim Y.H.;Bang Y.-J.;Chung H.C.;Ryu M.-H.;Alsina Maqueda M.;Longo Munoz F.;Cervantes Aguilar A.;Aranda Aguilar E.;Garcia Alfonso P.;Rivera F.;Feliu Batle J.;Pazo Cid R.;Kun-Huei Yeh;Chen J.-S.;Chao Y.;Yen C.-J.;?Zg?Ro?Lu M.;Kara O.;Yalcin S.;Hochhauser D.;Chau I.;Benson A.;Shankaran V.;Shaib W.;Philip P.;Sharma V.;Siegel R.;Sun W.;Wainberg Z.;George B.;Bullock A.;Myrick S.;Faruol J.;Siegel R.;Larson T.;Becerra C.;Ratnam S.;Richards D.A.;Riche S.L.;Keynote-061 Investigators; Shitara K.; ?zg?ro?lu M.; Bang Y.-J.; Di Bartolomeo M.; Mandal? M.; Ryu M.-H.; Fornaro L.; Olesi?ski T.; Caglevic C.; Chung H.C.; Muro K.; Goekkurt E.; Mansoor W.; McDermott R.S.; Shacham-Shmueli E.; Chen X.; Mayo C.; Kang S.P.; Ohtsu A.; Fuchs C.S.; Lerzo G.; O'Connor J.M.; Mendez G.A.; Lynam J.; Tebbutt N.; Wong M.; Strickland A.; Karapetis C.; Goldstein D.; Vasey P.; Van Laethem J.-L.; Van Cutsem E.; Berry S.; Vincent M.; Muller B.; Rey F.; Zambrano A.; Guerra J.; Krogh M.; Baeksgaard L.; Yilmaz M.; Elme A.; Magi A.; Auvinen P.; Alanko T.; Moehler M.; Kunzmann V.; Seufferlein T.; Thuss-Patience P.; Goekkurt E.; Hoehler T.; Haag G.; Al-Batran S.-E.; Castro H.; Lopez K.; Aguilar Vasquez M.; Sandoval M.; Lam K.O.; Cuffe S.; Kelly C.; Geva R.; Shacham-Shmueli E.; Hubert A.; Beny A.; Brenner B.; Giuseppe A.; Falcone A.; Maiello E.; Passalacqua R.; Montesarchio V.; Hara H.; Chin K.; Nishina T.; Komatsu Y.; Machida N.; Hironaka S.; Satoh T.; Tamura T.; Sugimoto N.; Cho H.; Omuro Y.; Kato K.; Goto M.; Hyodo I.; Yoshida K.; Baba H.; Esaki T.; Furuse J.; Wan Mohammed W.Z.; Hernandez Hernandez C.; Casas Garcia J.; Dominguez Andrade A.; Clarke K.; Hjortland G.; Glenjen N.; Kubiatowski T.; Jacek J.; Wojtukiewicz M.; Lazarev S.; Lancukhay Y.; Afanasayev S.; Moiseyenko V.; Kostorov V.; Protsenko S.; Shirinkin V.; Sakaeva D.; Fadeeva N.; Yong W.P.; Ng C.H.M.; Robertson B.; Rapaport B.; Cohen G.; Dreosti L.; Ruff P.; Jacobs C.; Landers G.; Szpak W.; Roh S.-Y.; Lee J.; Kim Y.H.; Bang Y.-J.; Chung H.C.; Ryu M.-H.; Alsina Maqueda M.; Longo Munoz F.; Cervantes Aguilar A.; Aranda Aguilar E.; Garcia Alfonso P.; Rivera F.; Feliu Batle J.; Pazo Cid R.; KUN-HUEI YEH; Chen J.-S.; Chao Y.; Yen C.-J.; ?zg?ro?lu M.; Kara O.; Yalcin S.; Hochhauser D.; Chau I.; Benson A.; Shankaran V.; Shaib W.; Philip P.; Sharma V.; Siegel R.; Sun W.; Wainberg Z.; George B.; Bullock A.; Myrick S.; Faruol J.; Siegel R.; Larson T.; Becerra C.; Ratnam S.; Richards D.A.; Riche S.L.; KEYnote-061 investigators |
| 臺大學術典藏 |
2020-05-25T07:35:00Z |
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1�V4, as a single dose and multiple doses in patients with solid malignancies
|
Yamamoto N; Ryoo B.-Y; Keam B; Kudo M; Chia-Chi Lin; Kunieda F; Ball H.A; Moran D; Komatsu K; Takeda K; Fukuda M; Furuse J; Morita S; Doi T. |
| 臺大學術典藏 |
2020-04-10T12:51:20Z |
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion
|
Yeo W.; Yeoh E.-M.; Furuse J.; Han K.-H.; Chiun Hsu; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Chen P.-J.; Chen P.-J.;Furuse J.;Han K.-H.;Chiun Hsu;Lim H.-Y.;Moon H.;Qin S.;Ye S.-L.;Yeoh E.-M.;Yeo W. |
| 臺大學術典藏 |
2020-04-10T12:51:17Z |
Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
|
Yeo W.;Chen P.-J.;Furuse J.;Han K.-H.;Chiun Hsu;Lim H.-Y.;Moon H.;Qin S.;Yeoh E.-M.;Ye S.-L.; Yeo W.; Chen P.-J.; Furuse J.; Han K.-H.; Chiun Hsu; Lim H.-Y.; Moon H.; Qin S.; Yeoh E.-M.; Ye S.-L. |
| 國家衛生研究院 |
2019-02 |
A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements
|
Goyal, L;Bahleda, R;Furuse, J;Valle, JW;Moehler, MH;Oh, DY;Chang, HM;Kelley, RK;Javle, MM;Borad, MJ;Chen, LT;Uboha, NV;Klumpen, HJ;O'Dwyer, PJ;Li, DN;Morizane, C;Huang, J;Bridgewater, JA |
| 國家衛生研究院 |
2017-08 |
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
|
Ueno, M;Li, CP;Ikeda, M;Ishii, H;Mizuno, N;Yamaguchi, T;Ioka, T;Oh, DY;Ichikawa, W;Okusaka, T;Matsuyama, Y;Arai, D;Chen, LT;Park, YS;Furuse, J |
| 國家衛生研究院 |
2016-08 |
Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma
|
Zhu, AX;Chen, D;He, W;Kanai, M;Voi, M;Chen, LT;Daniele, B;Furuse, J;Kang, YK;Poon, RT;Vogel, A;Chiang, DY |
| 國家衛生研究院 |
2014-07-02 |
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib the EVOLVE-1 randomized clinical trial
|
Zhu, AX;Kudo, M;Assenat, E;Cattan, S;Kang, YK;Lim, HY;Poon, RTP;Blanc, JF;Vogel, A;Chen, CL;Dorval, E;Peck-Radosavljevic, M;Santoro, A;Daniele, B;Furuse, J;Jappe, A;Perraud, K;Anak, O;Sellami, DB;Chen, LT |
| 國家衛生研究院 |
2014-01 |
EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib
|
Zhu, AX;Kudo, M;Assenat, E;Cattan, S;Kang, YK;Lim, HY;Poon, RTP;Blanc, JF;Vogel, A;Chen, CL;Dorval, E;Peck-Radosavljevic, M;Santoro, A;Daniele, B;Furuse, J;Jappe, A;Perraud, K;Anak, O;Sellami, DB;Chen, LT |
| 臺大學術典藏 |
2010 |
Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
|
Yeo W.; Chen P.-J.; Furuse J.; Han K.-H.; CHIUN HSU; Lim H.-Y.; Moon H.; Qin S.; Yeoh E.-M.; Ye S.-L. |
Showing items 1-25 of 25 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
